Hypertriglyceridemia is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hypertriglyceridemia have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hypertriglyceridemia compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hypertriglyceridemia overview
Hypertriglyceridemia is a condition in which the blood contains high levels of triglycerides, a type of fat that provides energy to the body. Triglycerides are important for normal metabolism, but excess amounts can increase the risk of cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hypertriglyceridemia can also cause acute pancreatitis, a serious inflammation of the pancreas that requires medical attention. Hypertriglyceridemia can be caused by genetic factors, obesity, diabetes, sedentary lifestyle, alcohol consumption, and certain medications. The diagnosis is based on a blood test that measures the fasting triglyceride level. A normal level is below 150 mg/dL, while a very high level is above 500 mg/dL. The treatment of hypertriglyceridemia involves lifestyle modifications, such as weight loss, exercise, dietary changes, and alcohol reduction. In some cases, medication may be prescribed to lower the triglyceride level and prevent complications.
For a complete picture of PTSR and LoA scores for drugs in Hypertriglyceridemia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
